KI
IOVA icon

Kula Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Kula Investments’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$276K Buy
45,194
+22,798
+102% +$157K 0.07% 477
2022
Q4 		$143K Buy
+22,396
New +$175K 0.04% 545

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kula Investments's IOVA Position: Q1 2023 in Review

Kula Investments increased its Iovance Biotherapeutics (IOVA) stake by 102% in Q1 2023, buying an estimated $157K and bringing the position to 45,194 shares worth $276K. The position accounts for 0.07% of the portfolio, ranked #477.

Kula Investments first reported a position in IOVA in Q4 2022 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Kula Investments held 45,194 shares of Iovance Biotherapeutics worth $276K as of Q1 2023.
  • Kula Investments bought 22,798 Iovance Biotherapeutics shares in Q1 2023, an estimated $157K.
  • Iovance Biotherapeutics made up 0.07% of Kula Investments's portfolio in Q1 2023, its #477 holding.
  • Kula Investments first reported a position in Iovance Biotherapeutics in Q4 2022 and has held it in 2 quarters since.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.